Analytical Data
-
Gene name
VACWR150
- Application
-
Alternative Names
/
-
Species
Vaccinia virus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11258
-
Expression Region
1-110aa
-
Molecular Weight
17.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VACWR150 is a recombinant protein derived from the VACV (Vaccinia Virus), a member of the Poxviridae family, which has garnered significant attention in recent years due to its potential applications in vaccine development and cancer therapy. Research on VACWR150 focuses on its immunogenic properties and its ability to elicit robust immune responses. As a model organism in virology, Vaccinia Virus has been instrumental in the development of live attenuated vaccines, with historical significance as the vaccine that eradicated smallpox. The recombinant form, VACWR150, is engineered to enhance its safety and efficacy, minimizing the pathogenicity associated with wild-type viruses while retaining its immunogenic capabilities. This makes VACWR150 a promising candidate for stimulating both humoral and cellular immunity against various infectious diseases and tumors. Studies have shown that VACWR150 can effectively prime T-cell responses, leading to a better understanding of viral pathogenesis and immunity. As the field of immunotherapy continues to evolve, VACWR150 stands out for its potential to be incorporated into therapeutic strategies for enhancing immune responses against cancer and infectious agents, providing a foundation for future vaccine innovations and therapeutic interventions. Given the rising need for effective vaccines and treatments in response to emerging global health threats, the exploration of VACWR150 serves as a critical component of current biomedical research aimed at combating diseases with innovative and effective solutions.
